CESCA THERAPEUTICS INC. (NASDAQ:KOOL) Files An 8-K Other Events
Item 8.01.
Other Events. |
Cesca Therapeutics Inc. (the Company) is filing this Current
Report on Form 8-K to update the description of its common stock
in its SEC filings.
Shares Authorized for Issuance
As of May 18, 2017, the Company is authorized, under its Sixth
Amended and Restated Certificate of Incorporation, as amended
(Certificate of Incorporation), to issue up to 350,000,000 shares
of common stock, $0.001 par value, and 2,000,000 shares of
preferred stock, $0.001 par value.
Common Stock
Each holder of the Companys common stock is entitled to one vote
for each share held on all matters submitted to a vote of the
stockholders, except matters that relate only to any outstanding
series of preferred stock that the Company may designate in the
future. No holder has any cumulative voting rights. Accordingly,
the holders of a majority of the shares of common stock entitled
to vote in any election of directors can elect all of the
directors standing for election, if they so choose.
Subject to preferences that may be applicable to any then
outstanding preferred stock, holders of common stock are entitled
to receive ratably those dividends, if any, as may be declared
from time to time by the board of directors out of legally
available funds. In the event of liquidation, dissolution or
winding up of the Company, holders of common stock will be
entitled to share ratably in the net assets legally available for
distribution to stockholders after the payment of all of debts
and other liabilities and the satisfaction of any liquidation
preference granted to the holders of any outstanding shares of
preferred stock.
Holders of common stock have no preemptive or conversion rights
or other subscription rights, and there are no redemption or
sinking fund provisions applicable to the common stock. All
outstanding shares of common stock are fully paid and
non-assessable. The rights, preferences, and privileges of the
holders of common stock are subject to, and may be adversely
affected by, the rights of the holders of shares of any series of
preferred stock that the Company may designate in the future.
Preferred Stock
The Company may, from time to time, issue preferred stock with
the rights, preferences and privileges established by the
Companys board of directors.
Effect of Certain Provisions of Certificate of Incorporation
and Bylaws
Some provisions of Delaware law and the Companys Certificate of
Incorporation and Restated Bylaws contain provisions that could
make the following transactions more difficult:
acquisition of the Company by means of a tender offer;
acquisition of the Company by means of a proxy contest or
otherwise; or
removal of the Companys incumbent officers and directors.
These provisions, summarized below, are expected to discourage
coercive takeover practices and inadequate takeover bids and to
promote stability in the Companys management. These provisions
are also designed to encourage persons seeking to acquire control
of the Company to first negotiate with the Companys board of
directors.
|
Undesignated Preferred Stock. The ability to |
|
Stockholder Meetings. The Companys Restated Bylaws |
|
Requirements for Advance Notification of Stockholder |
|
Board of Directors Size and Vacancies. |
Exchange Listing
The Companys common stock is listed on the NASDAQ Capital Market
under the symbol KOOL.
About CESCA THERAPEUTICS INC. (NASDAQ:KOOL)
Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood. CESCA THERAPEUTICS INC. (NASDAQ:KOOL) Recent Trading Information
CESCA THERAPEUTICS INC. (NASDAQ:KOOL) closed its last trading session up +0.05 at 3.14 with 4,855 shares trading hands.